JP6382945B2 - ジヒドロピラジノ−ピラジンによる癌治療 - Google Patents

ジヒドロピラジノ−ピラジンによる癌治療 Download PDF

Info

Publication number
JP6382945B2
JP6382945B2 JP2016509051A JP2016509051A JP6382945B2 JP 6382945 B2 JP6382945 B2 JP 6382945B2 JP 2016509051 A JP2016509051 A JP 2016509051A JP 2016509051 A JP2016509051 A JP 2016509051A JP 6382945 B2 JP6382945 B2 JP 6382945B2
Authority
JP
Japan
Prior art keywords
dihydropyrazino
compound
pyrazine
methyl
mgmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016509051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516816A (ja
JP2016516816A5 (OSRAM
Inventor
ライモン ヘザー
ライモン ヘザー
マエ ヘゲ クリステン
マエ ヘゲ クリステン
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー, シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2016516816A publication Critical patent/JP2016516816A/ja
Publication of JP2016516816A5 publication Critical patent/JP2016516816A5/ja
Application granted granted Critical
Publication of JP6382945B2 publication Critical patent/JP6382945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
JP2016509051A 2013-04-17 2014-04-16 ジヒドロピラジノ−ピラジンによる癌治療 Active JP6382945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361813071P 2013-04-17 2013-04-17
US61/813,071 2013-04-17
PCT/US2014/034304 WO2014172425A1 (en) 2013-04-17 2014-04-16 Treatment of cancer with dihydropyrazino-pyrazines

Publications (3)

Publication Number Publication Date
JP2016516816A JP2016516816A (ja) 2016-06-09
JP2016516816A5 JP2016516816A5 (OSRAM) 2017-05-18
JP6382945B2 true JP6382945B2 (ja) 2018-08-29

Family

ID=50736197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509051A Active JP6382945B2 (ja) 2013-04-17 2014-04-16 ジヒドロピラジノ−ピラジンによる癌治療

Country Status (20)

Country Link
US (2) US9630966B2 (OSRAM)
EP (2) EP4218763A1 (OSRAM)
JP (1) JP6382945B2 (OSRAM)
KR (1) KR102271344B1 (OSRAM)
CN (2) CN113730412A (OSRAM)
AU (1) AU2014254052B2 (OSRAM)
BR (1) BR112015026238A8 (OSRAM)
CA (1) CA2908353C (OSRAM)
EA (1) EA030808B1 (OSRAM)
ES (1) ES2944478T3 (OSRAM)
IL (1) IL241950B (OSRAM)
MX (2) MX377267B (OSRAM)
NI (1) NI201500150A (OSRAM)
NZ (1) NZ629332A (OSRAM)
PH (3) PH12021552945B1 (OSRAM)
SA (1) SA515370012B1 (OSRAM)
SG (2) SG11201508223YA (OSRAM)
TW (2) TWI631950B (OSRAM)
UA (1) UA119538C2 (OSRAM)
WO (1) WO2014172425A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ629469A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
NZ629230A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US10308656B2 (en) 2015-08-18 2019-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of Ku70/80 and uses thereof
WO2018004258A1 (ko) * 2016-06-28 2018-01-04 한미약품 주식회사 신규한 헤테로시클릭 유도체 화합물 및 이의 용도
KR20180002053A (ko) * 2016-06-28 2018-01-05 한미약품 주식회사 신규한 헤테로시클릭 유도체 화합물 및 이의 용도
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
US20240294478A1 (en) * 2021-06-18 2024-09-05 Yale University Anti-cancer compounds and methods of use

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en) 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4294836A (en) 1980-03-24 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4294837A (en) 1980-03-28 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4317909A (en) 1980-03-24 1982-03-02 Sterling Drug Inc. Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4309537A (en) 1980-03-28 1982-01-05 Sterling Drug Inc. Production of imidazo[4,5-b]pyridin-2-ones or thiones
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPS63275582A (ja) 1987-05-02 1988-11-14 Naade Kenkyusho:Kk ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de) 1987-07-10 1988-11-16 Akad Wissenschaften Ddr Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
TW274550B (OSRAM) 1992-09-26 1996-04-21 Hoechst Ag
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US6031105A (en) 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
UA72448C2 (en) 1997-09-26 2005-03-15 Zentaris Gmbh Azabenzimidazole-based compounds, methods for their synthesis and pharmaceutical composition, method for modulating function of serine/threonine protein kinases with azabenzimidazole-based compounds, method for identifying compounds modulating functioning of serine/threonine protein kinase, method for preventing and treating serine/threonine protein kinase-related abnormal conditions with azabenzimidazole-based compounds
US6800436B1 (en) 1997-11-27 2004-10-05 Chugai Seiyaku Kabushiki Kaisha Diagnostic method, diagnostic reagent and therapeutic preparation for diseases caused by variation in LKB1 gene
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
EP1186232A4 (en) 1999-05-31 2004-11-10 Chugai Pharmaceutical Co Ltd 'KNOCKOUT' ANIMALS LACKING THE LKB1 GENE
JP2003146987A (ja) 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP2002100363A (ja) 2000-09-25 2002-04-05 Mitsubishi Chemicals Corp リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
JP2002167387A (ja) 2000-11-29 2002-06-11 Dainippon Pharmaceut Co Ltd ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
AU2002220276A1 (en) 2000-12-12 2002-06-24 Neurogen Corporation Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
HRP20040213A2 (en) 2001-09-04 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
MY156407A (en) 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
US20040204420A1 (en) 2002-08-05 2004-10-14 Rana Tariq M. Compounds for modulating RNA interference
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
US7423148B2 (en) 2002-11-21 2008-09-09 Chiron Corporation Small molecule PI 3-kinase inhibitors and methods of their use
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
WO2004076454A1 (de) 2003-02-26 2004-09-10 Boehringer Ingelheim Pharma Gmbh & Co Kg Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
SI2604620T2 (sl) 2003-05-30 2024-10-30 Gilead Pharmasset Llc Modificirani fluorirani nukleozidni analogi
WO2005013894A2 (en) 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
DK1651673T3 (da) 2003-07-17 2008-08-18 Univ Dundee Fremgangsmåder til anvendelse af et LKB1/STRAD/MO25-kompleks
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
US20080194019A1 (en) 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (ja) 2004-06-23 2006-01-05 Banyu Pharmaceutical Co., Ltd. ２－アリールプリン誘導体の製造方法
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1796467A4 (en) 2004-09-24 2009-07-01 Janssen Pharmaceutica Nv INHIBITORS IMIDAZO {4,5-B} PYRAZINONE PROTEIN KINASES
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR20070085286A (ko) 2004-10-29 2007-08-27 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 바이사이클릭 피리미딘 유도체
WO2006052976A2 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
KR20070113252A (ko) 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-디아미노-피리도피리미딘 유도체 및 이의 ｍＴＯＲ억제제로서의 용도
JP2008531537A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 化合物
KR20080013886A (ko) 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
KR20140105621A (ko) 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
EP1931645B1 (en) 2005-10-07 2014-07-16 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
US8247408B2 (en) 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
WO2007047754A2 (en) 2005-10-18 2007-04-26 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
CA2630271C (en) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Fused bicyclic mtor inhibitors
HRP20120963T1 (hr) 2005-11-22 2012-12-31 Kudos Pharmaceuticals Ltd PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
US20110034454A1 (en) 2006-01-11 2011-02-10 Allan Paul Dishington Morpholino pyrimidine derivatives and their use in therapy
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
US20090076009A1 (en) 2006-05-03 2009-03-19 Arnould Jean-Claude Retired Thiazole derivatives and their use as anti-tumour agents
US20090118336A1 (en) 2006-05-03 2009-05-07 Laurent David Pyrazole derivatives and their use as pi3k inhibitors
JP2009537621A (ja) 2006-05-22 2009-10-29 アストラゼネカ アクチボラグ インドール誘導体
DK2583970T3 (en) 2006-08-02 2015-11-16 Cytokinetics Inc Certain chemical entities, compositions, and methods comprising imidazopyrimidines
BRPI0715888B1 (pt) 2006-08-23 2021-11-03 Kudos Pharmaceuticals Limited Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
WO2008030744A2 (en) 2006-09-05 2008-03-13 Board Of Regents, The University Of Texas System Inhibitors of c-met and uses thereof
CA2662677C (en) 2006-09-05 2016-05-31 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032064A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
CN101563340A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
EP2069330A1 (en) 2006-09-14 2009-06-17 AstraZeneca AB 2 -benzimidazolyl- 6 -morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032027A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008043031A1 (en) 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ZA200902384B (en) 2006-10-19 2010-07-28 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
CN105693730A (zh) 2006-10-19 2016-06-22 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
GEP20125436B (en) 2006-11-20 2012-03-26 Novartis Ag Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
EP2074118A2 (en) 2007-07-09 2009-07-01 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ATE554075T1 (de) 2007-07-09 2012-05-15 Astrazeneca Ab Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
AU2008312631A1 (en) 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2712267A1 (en) 2008-01-15 2009-07-23 Wyeth Llc 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20110091574A1 (en) 2008-02-15 2011-04-21 Catholic Healthcare West Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox2 inhibitor
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP5930278B2 (ja) 2008-11-25 2016-06-08 ユニバーシティー オブ ロチェスター Ｍｌｋ阻害剤および使用方法
US8476270B2 (en) 2009-09-14 2013-07-02 Gilead Sciences, Inc. Dihydropyrido[4,3-b]pyrazine-3-ones as modulators of toll-like receptors
CA2778615C (en) 2009-10-26 2019-04-23 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
KR20120120252A (ko) 2009-12-23 2012-11-01 엘란 파마슈티칼스, 인크. 폴로-유사 키나제의 억제제로서의 프테리디논
MX2012009030A (es) 2010-02-03 2012-09-12 Signal Pharm Llc Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa.
US20110318336A1 (en) 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
MX2014001246A (es) 2011-08-03 2014-06-11 Signal Pharm Llc Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
US9493466B2 (en) 2011-10-19 2016-11-15 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
NZ628410A (en) 2012-02-24 2016-03-31 Signal Pharm Llc Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
EP2825170B1 (en) 2012-03-15 2018-05-09 Signal Pharmaceuticals, LLC Treatment of cancer with tor kinase inhibitors
MX359227B (es) 2012-03-15 2018-09-20 Signal Pharm Llc Tratamiento de cáncer con inhibidores de tor cinasa.
WO2013138556A1 (en) 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
NZ628407A (en) 2012-03-15 2016-04-29 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ629230A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
WO2014172429A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
NZ629469A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
US20140314673A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer

Also Published As

Publication number Publication date
WO2014172425A1 (en) 2014-10-23
PH12015502292B1 (en) 2019-06-28
US20140314674A1 (en) 2014-10-23
TWI631950B (zh) 2018-08-11
KR102271344B1 (ko) 2021-07-01
NI201500150A (es) 2015-11-30
MX377267B (es) 2025-03-07
MX2020004995A (es) 2020-08-27
EA030808B1 (ru) 2018-09-28
US9630966B2 (en) 2017-04-25
CN105473142A (zh) 2016-04-06
US20170182044A1 (en) 2017-06-29
TW201742626A (zh) 2017-12-16
CN113730412A (zh) 2021-12-03
BR112015026238A8 (pt) 2019-12-24
AU2014254052A1 (en) 2015-10-29
MX2015014589A (es) 2016-04-25
AU2014254052B2 (en) 2019-06-06
HK1221145A1 (en) 2017-05-26
US10183019B2 (en) 2019-01-22
KR20160007502A (ko) 2016-01-20
SA515370012B1 (ar) 2017-12-18
BR112015026238A2 (pt) 2017-07-25
EP4218763A1 (en) 2023-08-02
CA2908353C (en) 2021-11-02
SG10201801965RA (en) 2018-04-27
EA201591987A1 (ru) 2016-03-31
PH12021552945A1 (en) 2022-07-18
EP2986299A1 (en) 2016-02-24
TWI604843B (zh) 2017-11-11
JP2016516816A (ja) 2016-06-09
ES2944478T3 (es) 2023-06-21
NZ629332A (en) 2017-05-26
PH12021552945B1 (en) 2024-02-28
EP2986299B1 (en) 2023-03-29
PH12015502292A1 (en) 2016-02-10
TW201526892A (zh) 2015-07-16
CA2908353A1 (en) 2014-10-23
IL241950B (en) 2019-06-30
PH12018502731A1 (en) 2020-05-04
SG11201508223YA (en) 2015-11-27
UA119538C2 (uk) 2019-07-10

Similar Documents

Publication Publication Date Title
JP6382945B2 (ja) ジヒドロピラジノ−ピラジンによる癌治療
CN103998036B (zh) 利用tor激酶抑制剂治疗癌症
EP2825170B1 (en) Treatment of cancer with tor kinase inhibitors
JP6382947B2 (ja) 前立腺癌を治療するためのジヒドロピラジノ−ピラジン化合物及びアンドロゲン受容体アンタゴニストを含む組合せ療法
JP6382946B2 (ja) ジヒドロピラジノ−ピラジンによる癌治療
JP2016522177A (ja) ジヒドロピラジノ−ピラジンによる癌治療
JP2017514806A (ja) Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
HK1221145B (en) 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for treating glioblastoma multiforme
HK1243919B (zh) 利用tor激酶抑制剂治疗癌症

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180802

R150 Certificate of patent or registration of utility model

Ref document number: 6382945

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250